Claims
- 1. A method of treating asthma in human, the method comprising administering to the human a therapeutically effective amount of formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, or a pharmaceutically acceptable salt thereof.
- 2. The method according to claim 1, wherein the amount of formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, or a pharmaceutically acceptable salt thereof, is administered orally, transdermally, by inhalation, by subcutaneous injection or by intravenous infusion.
- 3. The method according to claim 2, wherein the amount of formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, or a pharmaceutically acceptable salt thereof, is administered by inhalation at a dosage of about 1 μg to about 100 μg per day.
- 4. The method according to claim 3, wherein the amount of formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, or a pharmaceutically acceptable salt thereof, is administered is about 6 μg to about 25 μg per day.
- 5. The method according to claim 3, wherein the formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, comprises formoterol fumarate dihydrate.
- 6. The method according to claim 5, wherein the formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, comprises formoterol fumarate dihydrate.
- 7. A method of treating or preventing bronchospasm in a human, the method comprising administering to the human a therapeutically effective amount of formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, or a pharmaceutically acceptable salt thereof.
- 8. The method according to claim 7, wherein the amount of formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, or a pharmaceutically acceptable salt thereof, is administered orally, transdermally, by inhalation, by subcutaneous injection or by intravenous infusion.
- 9. The method according to claim 8, wherein the amount of formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, or a pharmaceutically acceptable salt thereof, is administered by inhalation at a dosage of about 1 μg to about 100 μg per day.
- 10. The method according to claim 9, wherein the amount of formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, or a pharmaceutically acceptable salt thereof, is administered is about 6 μg to about 25 μg per day.
- 11. The method according to claim 9, wherein the formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, comprises formoterol fumarate dihydrate.
- 12. The method according to claim 11, wherein the formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, comprises formoterol fumarate dihydrate.
- 13. A method of eliciting bronchodilation effect in a human, the method comprising administering to the human a therapeutically effective amount of formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, or a pharmaceutically acceptable salt thereof.
- 14. The method according to claim 13, wherein the amount of formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, or a pharmaceutically acceptable salt thereof, is administered orally, transdermally, by inhalation, by subcutaneous injection or by intravenous infusion.
- 15. The method according to claim 14, wherein the amount of formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, or a pharmaceutically acceptable salt thereof, is administered by inhalation at a dosage of about 1 μg to about 100 μg per day.
- 16. The method according to claim 15, wherein the amount of formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, or a pharmaceutically acceptable salt thereof, is administered is about 6 μg to about 25 μg per day.
- 17. The method according to claim 15, wherein the formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, comprises formoterol fumarate dihydrate.
- 18. The method according to claim 17, wherein the formoterol containing at least 90% by weight (R,R)-formoterol and 10% or less by weight (S,S)-formoterol, comprises formoterol fumarate dihydrate.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9107196 |
Apr 1991 |
GB |
|
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. Ser. No. 09/535,200, filed Mar. 27, 2000 as a continuation of U.S. Ser. No. 09/136,109 (now U.S. Pat. 6,068,833), filed Aug. 18, 1998 as a continuation of U.S. Ser. No. 08/613,382 (now U.S. Pat. No. 5,795,564), filed Mar. 7, 1996 as a continuation-in-part of U.S. Ser. No. 08/373,515 (now abandoned), filed Jan. 12, 1995 as a continuation-in-part of U.S. Ser. No. 08/222,319 (now abandoned), filed Apr. 4, 1994 as a continuation of U.S. Ser. No. 07/927,458 (now abandoned), filed Aug. 10, 1992. U.S. Ser. No. 09/136,109 also claims priority as a continuation-in-part of U.S. Ser. No. 08/382,744 (now abandoned), filed Feb. 2, 1995 as a continuation of U.S. Ser. No. 08/223,798 (now abandoned), filed Apr. 6, 1994 as a continuation of U.S. Ser. No. 07/862,907 (now abandoned), filed Apr. 3, 1992 claiming priority of Great Britain application 9107196.9, filed Apr. 5, 1991. The entire disclosures of each of the prior applications are incorporated herein by reference.
US Referenced Citations (7)
Foreign Referenced Citations (2)
Number |
Date |
Country |
2255503 |
Nov 1992 |
GB |
WO9205147 |
Apr 1992 |
WO |
Non-Patent Literature Citations (13)
Entry |
Hett et al, Enantio- and Diastereoselective Synthesis of all Four Steroisomers of Formoterol, Tet. Lett. 38, 1125-1128 (1997).* |
“Comparison of the Action of BD 40 A and some Other β-Adrenoceptor Stimulants of the Isolated Trachea and Atria of the Guinea Pig” H. Ida Arzneim.-Forsch. 26,839-842 (1976). |
“Cardiorespiratory Activities of 3-Formylamino-4-hydroxy α-(N-1-methyl-2-methoxyphenethylaminomethyl)-benzylalcohol-bemifumarate (BD 40 ) and some other β-Adrenoceptor Stimulants in Conscious Guinea Pigs” H. Ida Arzneim.-Forsch. 26, 1337-1340 (1976). |
“New β-Adrenoreceptor Stimulants. Studies on 3-Acylamino-4-hydroxy-α-(N-substituted aminomethyl)benzyl Alcohols” Murase et al. Chem. Pharm. Bull. 25(6) 1368-1377 (1977). |
“Steric Aspects of Agonism and Antagonism at β-Adrenoceptors: Synthesis of and Pharmacological Experiments With the Enantiomers of Formoterol and Their Diasteromers” Trofast et al. Chirality 3443-450 (1991). |
“A Three-Month Comparison of Twice Daily Inhaled Formoterol Versus Four Times Daily Inhaled Albuterol in the Management of Stable Asthma 1-3” Kesten et al. Am. Rev. Respir. Dis. 144 622-625 (1991). |
“Absolute Configurations of Four Isomers of 3-Formamido-4-hydroxy- . . . ” Murase et al. Chem. Pharm. Bull. 26, 1123-29 (1978). |
“β-Adrenoceptor Ligands: Characterization and Quantification of Drug Effects” Lemoine Quant. Struct.-Act. Relat. 11, 211-218 (1992). |
“Stereoselectivity in pharmacodynamics and pharmacokinetics” Ariëns Schjweiz. med. Wochenschr. 120, 131-134 (1990). |
“Racemic therapeutics-ethical and regulatory aspects” Ariëns Eur. J. Clin. Pharmacol 41, 89-93 (1991). |
“Racemates Versus Enantiomers in Drug Development: Dogmatism . . . ” Testa et al. Chirality 2, 129-133 (1990). |
Murase et al., “Absolute Configurations of four Isomers of 3-Formamido-4-hydroxy-α-[[N-(p-methoxy-α-methylphenethyl)amino]methyl]benzyl Alcohol, a Potent β-Adrenoreceptor Stimulant,” Chem. Pharm. Bull, 26:1123-29 (1978). |
Testa et al., “Racemates Versus Enatiomers in Drug Development: Dogmatism or Pragmatism?” Chirality, 2:129-133 (1990). |
Continuations (6)
|
Number |
Date |
Country |
Parent |
09/535200 |
Mar 2000 |
US |
Child |
09/927008 |
|
US |
Parent |
09/136109 |
Aug 1998 |
US |
Child |
09/535200 |
|
US |
Parent |
08/613382 |
Mar 1996 |
US |
Child |
09/136109 |
|
US |
Parent |
07/927458 |
Aug 1992 |
US |
Child |
08/222319 |
|
US |
Parent |
08/223798 |
Apr 1994 |
US |
Child |
08/382744 |
|
US |
Parent |
07/862907 |
Apr 1992 |
US |
Child |
08/223798 |
|
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
08/373515 |
Jan 1995 |
US |
Child |
08/613382 |
|
US |
Parent |
08/222319 |
Apr 1994 |
US |
Child |
08/373515 |
|
US |
Parent |
08/382744 |
Feb 1995 |
US |
Child |
09/136109 |
Aug 1998 |
US |